{"id":1000205,"date":"2026-09-03T07:29:57","date_gmt":"2026-09-03T11:29:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/"},"modified":"2026-09-03T07:29:57","modified_gmt":"2026-09-03T11:29:57","slug":"blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/","title":{"rendered":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Sept.  03, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gZ__ktb_j1SvGqVwVXwl7pZh7EASc2kyPmE1tIkopgouIdQVajRl-ZnJSMKNTWAK3ltlgcKQLqBcBDOJttaKFA1GPP0vl3OCmyAeO3oj5Yd5NjcfVqJRvq9yw3Xsi35v\" rel=\"nofollow\" target=\"_blank\"><u>BlossomHill Therapeutics, Inc.<\/u><\/a> (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.<\/p>\n<p>Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings.<\/p>\n<p>\n        <strong>Conference:<\/strong> 8th Annual RAS-Targeted Drug Development Summit<br \/><strong>Location:\u00a0<\/strong>The Colonnade Hotel, Boston<br \/><strong>Date:\u00a0<\/strong>Thursday, September 10<br \/><strong>Time:\u00a0<\/strong>10:00 am Pacific Time | 1:00 pm Eastern Time<\/p>\n<p>\n        <strong>Conference:\u00a0<\/strong> H.C. Wainwright 28th Annual Global Investment Conference<br \/><strong>Location:\u00a0<\/strong> Lotte New York Palace Hotel, Holmes Room II, 4<sup>th<\/sup> Floor, New York City<br \/><strong>Date:\u00a0<\/strong>Tuesday, September 15<br \/><strong>Time:\u00a0<\/strong>7:30 am Pacific Time | 10:30 am Eastern Time<\/p>\n<p>Webcast access for the H.C. Wainwright conference will be available on the\u00a0Investor Relations section of the company\u2019s website. An archived replay will be available for 90 days.<\/p>\n<p>\n        <strong>About BlossomHill Therapeutics<\/strong><br \/>\n        <br \/>BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development \u2013 including three FDA-approved drugs \u2013 BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company\u2019s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR<sup>TM<\/sup> inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R\/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). The company\u2019s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors. BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZdIrnxke79yIU9_yqKGJzDw88V30_nBqyUtclZlpIViGQTQaegnsL0lnfKcbz7_0maLfwaCl2Qq3AnY3N1uSR4AQqrkaGKDAaLaqodXGEZU=\" rel=\"nofollow\" target=\"_blank\">bhtherapeutics.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7SphqhcvvnMSdfJVHyakPcPOWsCgtOBcf-ftuzfUHn8CsvdcBu0TS421gLnWAdRuHyFUMWub4FUNJCq1LTGZC6mKq8MdzHlqctV9RcdIEbf-PYg5bLZfmXNVbmGUzmSR-0GlBjPpBFxixLwdsGSpFskNW5gMRwaTwyGH4PiUjC8=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qt-yUG_Ah650HvESM2vNFywM8SUc0k7n3bSltOqBtLJuIHIYzi3zx0WK2qqHLJ2lzRqW8822xpqgCWGiwYUrDQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Company Contact: <\/strong><br \/>\n        <br \/>Michael Moore, BlossomHill Therapeutics<br \/>michael.moore@bhtherapeutics.com<\/p>\n<p>\n        <strong>Media: <\/strong><br \/>\n        <br \/>Ashlea Kosikowski, 1AB <br \/>ashlea@1abmedia.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmM2NDA2MDYtMTkwYy00NjJkLTg0ZWYtZWYxYzhmNWMyNzA1LTEyMTkxMDYtMjAyNi0wOS0wMy1lbg==\/tiny\/BlossomHill-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings. Conference: 8th Annual RAS-Targeted Drug Development SummitLocation:\u00a0The Colonnade Hotel, BostonDate:\u00a0Thursday, September 10Time:\u00a010:00 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000205","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings. Conference: 8th Annual RAS-Targeted Drug Development SummitLocation:\u00a0The Colonnade Hotel, BostonDate:\u00a0Thursday, September 10Time:\u00a010:00 &hellip; Continue reading &quot;BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T11:29:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference\",\"datePublished\":\"2026-09-03T11:29:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"wordCount\":440,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"name\":\"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\",\"datePublished\":\"2026-09-03T11:29:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","og_description":"SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings. Conference: 8th Annual RAS-Targeted Drug Development SummitLocation:\u00a0The Colonnade Hotel, BostonDate:\u00a0Thursday, September 10Time:\u00a010:00 &hellip; Continue reading \"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-03T11:29:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference","datePublished":"2026-09-03T11:29:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/"},"wordCount":440,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/","name":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=","datePublished":"2026-09-03T11:29:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDA3OCM3ODE0Mzc3IzIyMDc1NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit &amp; H.C. Wainwright 28th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000205"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000205\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}